Latest news with #CAH
Yahoo
5 days ago
- Business
- Yahoo
Cardinal Health (CAH) Falls on Dismal Revenue Performance
We recently published Cardinal Health, Inc. (NYSE:CAH) is one of the worst-performing stocks on Tuesday. Cardinal Health dropped its share prices by 7.21 percent on Tuesday to finish at $146.3 apiece as investors soured on its dismal revenue performance in both the fourth quarter and the full fiscal period of 2025. In its updated report, Cardinal Health, Inc. (NYSE:CAH) said revenues in the fourth quarter of the year finished flat at $60 billion, but attributable net income grew by 11 percent to $501 million from $450 million in the same period last year. In the full fiscal year of 2025, revenues decreased by 2 percent to $222.6 billion from $226.8 billion last year. Attributable net income, however, grew by 7 percent to $2 billion from $1.9 billion year-on-year. In other news, Cardinal Health, Inc. (NYSE:CAH) announced the acquisition of Solaris Health through its management services organization (MSO), The Specialty Alliance. A dose bottle of the medication is in the medical tech's hand Under the transaction, Cardinal Health, Inc. (NYSE:CAH) will infuse $1.9 billion in cash into The Specialty Alliance, in turn, raising its ownership in the latter to approximately 75 percent. Cardinal Health said it expects the transaction to close by the end of the year, subject to closing conditions, including the receipt of required physician and regulatory approvals. While we acknowledge the potential of CAH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the .
Yahoo
6 days ago
- Business
- Yahoo
Cardinal Health Lifts Fiscal 2026 Earnings Outlook; Strikes $1.9 Billion Deal to Buy Solaris Health
Cardinal Health (CAH) raised its full-year earnings outlook on Tuesday after its fiscal fourth-quart Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Business
- Yahoo
Cardinal Health Reports Fourth Quarter and Fiscal Year 2025 Results and Raises Fiscal Year 2026 Guidance
Fourth quarter revenue was relatively flat at $60.2 billion; revenue increased 21% excluding the impact of a previously communicated contract expiration Fourth quarter GAAP1 operating earnings were $428 million and GAAP diluted EPS was $1.00 Fourth quarter non-GAAP operating earnings increased 19% to $719 million and non-GAAP diluted EPS increased 13% to $2.08 Fiscal Year 2025 adjusted free cash flow was $2.5 billion Fiscal year 2026 non-GAAP EPS guidance2 raised to $9.30 to $9.50, from $9.10 to $9.30 Company announces the acquisition of Solaris Health, the country's leading urology MSO DUBLIN, Ohio, Aug. 12, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported fourth quarter fiscal year 2025 revenues of $60.2 billion, relatively flat to the fourth quarter of fiscal year 2024. Fourth quarter revenue increased 21% excluding the impact of a previously communicated customer contract expiration. GAAP operating earnings were $428 million and GAAP diluted earnings per share (EPS) were $1.00. Non-GAAP operating earnings increased 19% to $719 million, driven by segment profit increases across Pharmaceutical and Specialty Solutions, GMPD and Other3. Non-GAAP diluted EPS increased 13% to $2.08 in the quarter, reflecting the increase in non-GAAP operating earnings and a lower share count, partially offset by an increase in interest and other expense due to financing costs related to recent acquisitions and a higher non-GAAP effective tax rate. Fiscal year 2025 revenues were $222.6 billion, a 2% decrease from fiscal year 2024. Fiscal year 2025 revenue increased 18% excluding the impact of a previously communicated customer contract expiration. GAAP operating earnings were $2.3 billion and GAAP diluted EPS was $6.45. Non-GAAP operating earnings increased 15% to $2.8 billion, driven primarily by segment profit increases in Pharmaceutical and Specialty Solutions and Other. Non-GAAP diluted EPS increased 9% to $8.24 for the year, reflecting the increase in non-GAAP operating earnings across the business and a lower share count following in-year share repurchases, partially offset by higher interest and other expense and a higher non-GAAP effective tax rate. "Fiscal 2025 was a transformative year for Cardinal Health, and we closed the year with momentum, delivering strong fourth quarter results," said Jason Hollar, CEO of Cardinal Health. "The broad-based operational strength, with all five of our operating segments growing profit double-digits, reflects the disciplined execution of our strategy and our investments for growth. We enter Fiscal 2026 with confidence, evidenced by our increased financial outlook, as we continue to evolve towards reaching our full potential." Q4 and full year FY25 summaryQ4 FY25Q4 FY24Y/YFY25FY24Y/Y Revenue $60.2 billion$59.9 billion— %$222.6 billion$226.8 billion(2) % Operating earnings $428 million$401 million7 %$2.3 billion$1.2 billion83 % Non-GAAP operating earnings $719 million$605 million19 %$2.8 billion$2.4 billion15 % Net earnings attributable to Cardinal Health, Inc. $239 million$235 million2 %$1.6 billion$852 million83 % Non-GAAP net earnings attributable to Cardinal Health, Inc. $501 million$450 million11 %$2.0 billion$1.9 billion7 % Effective Tax Rate 36.9 %40.4 %25.3 %28.9 % Non-GAAP Effective Tax Rate 26.3 %24.6 %23.3 %21.7 % Diluted EPS attributable to Cardinal Health, Inc. $1.00$0.964 %$6.45$3.4587 % Non-GAAP diluted EPS attributable to Cardinal Health, Inc. $2.08$1.8413 %$8.24$7.539 % Segment results Pharmaceutical and Specialty Solutions segmentQ4 FY25Q4 FY24Y/YFY25FY24Y/Y Revenue $55.4 billion$55.6 billion— %$204.6 billion$210.0 billion(3) % Segment profit $535 million$482 million11 %$2.3 billion$2.0 billion12 % Fourth-quarter revenue for the Pharmaceutical and Specialty Solutions segment was relatively flat at $55.4 billion. Fourth-quarter revenue increased 22% excluding the impact of the customer contract expiration, driven by brand and specialty pharmaceutical sales growth from existing and new customers. Pharmaceutical and Specialty Solutions segment profit increased 11% to $535 million in the fourth quarter, driven by the acquisition of MSO platforms and contributions from brand and specialty products, partially offset by the customer contract expiration. Global Medical Products and Distribution segmentQ4 FY25Q4 FY24Y/YFY25FY24Y/Y Revenue $3.2 billion$3.1 billion3 %$12.6 billion$12.4 billion2 % Segment profit $70 million$47 million49 %$135 million$92 million47 % Fourth-quarter revenue for the Global Medical Products and Distribution segment increased 3% to $3.2 billion, driven by volume growth from existing customers. Global Medical Products and Distribution segment profit increased 49% to $70 million in the fourth quarter, driven by volume growth from existing customers. Other3Q4 FY25Q4 FY24Y/YFY25FY24Y/Y Revenue $1.6 billion$1.2 billion37 %$5.4 billion$4.5 billion19 % Segment profit $160 million$111 million44 %$516 million$423 million22 % Fourth-quarter revenue for Other increased 37% to $1.6 billion, driven by growth across the three operating segments: at-Home Solutions (including the acquisition of Advanced Diabetes Supply), Nuclear and Precision Health Solutions and OptiFreight Logistics. Other segment profit increased 44% to $160 million in the fourth quarter, driven by growth across the three operating segments: at-Home Solutions (including the acquisition of Advanced Diabetes Supply), Nuclear and Precision Health Solutions and OptiFreight Logistics. Fiscal year 2026 outlook2The company raised its fiscal year 2026 outlook for non-GAAP diluted EPS to $9.30 to $9.50 (+13% to +15% growth), a $0.20 increase from the preliminary outlook of $9.10 to $9.30 previously communicated during the company's 2025 Investor Day. Non-GAAP earnings per share $9.30 to $9.50 Pharmaceutical and Specialty Solutions segment:Revenue 11% to 13% growth Segment profit 11% to 13% growth Global Medical Products and Distribution segment:Revenue 2% to 4% growth Segment profit At least $140 million Other (NPHS, at-Home Solutions, OptiFreight Logistics):Revenue 26% to 28% growth Segment profit 25% to 27% growth Interest and other ~$275 million Non-GAAP effective tax rate 22.0% - 24.0% Diluted weighted average shares outstanding 238 million to 240 million Share repurchases ~$750 million Capital Expenditures ~$600 million Non-GAAP adjusted free cash flow $2.75 billion to $3.25 billionBold indicates a change to the preliminary FY26 outlook provided in the Investor Day press release on June 12, 2025. The increase to non-GAAP diluted EPS reflects a benefit to net earnings of classifying the shares held by physicians and management of The Specialty Alliance as a liability as opposed to non-controlling interests within equity and increased contributions from the Pharmaceutical and Specialty Solutions segment and the growth businesses reported in Other.3 Recent highlights Cardinal Health hosted an Investor Day on June 12th, 2025 where management detailed the company's momentum, growth strategies and updated long-term value creation plans Cardinal Health announced that the company entered into a definitive agreement to acquire Solaris Health, the country's leading urology MSO with over 750 providers. Solaris Health will join the Specialty Alliance's Urology Alliance and advances Cardinal Health's multi-specialty growth strategy Cardinal Health hosted its 33rd annual Retail Business Conference, bringing together approximately 5,000 attendees from across the country to celebrate the critical role its independent pharmacy customers play in caring for their communities and highlight the company's innovations and commitment to its customers Cardinal Health announced the launch of the Cardinal Health™ One Voice Initiative for pharmacy advocacy, which provides direct financial assistance to state pharmacy associations for the purpose of supporting independent pharmacists' advocacy efforts Cardinal Health announced the U.S. launch of Kendall DL™ Multi System, its multi-parameter, single-patient use monitoring cable and lead wire system that enables the continuous monitoring of cardiac activity, blood oxygen level and temperature with one point of connection Cardinal Health released its inaugural cell and gene therapy industry report providing insights into the current landscape and promising potential of cell and gene therapies The Cardinal Health Foundation expanded its Equity Rx program across Ohio and three new states, increasing access to affordable medications and supporting Ohio's first statewide prescription drug repository WebcastCardinal Health will host a webcast today at 8:30 a.m. ET to discuss fourth quarter and full year results. To access the webcast and corresponding slide presentation, go to the Investor Relations page at No access code is required. Presentation slides and a webcast replay will be available until August 13, 2026. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuclear pharmacies and manufacturing facilities; and a provider of performance and data solutions. Our company's customer-centric focus drives continuous improvement and leads to innovative solutions that improve people's lives every day. Learn more about Cardinal Health at and in our Newsroom. ContactsMedia: Erich Timmerman, and 614.757.8231Investors: Matt Sims, and 614.553.3661 1GAAP refers to U.S. generally accepted accounting principles. This news release includes GAAP financial measures as well as non-GAAP financial measures, which are financial measures not calculated in accordance with GAAP. See "Use of Non-GAAP Measures" following the attached schedules for definitions of the non-GAAP financial measures presented in this news release and see the attached schedules for reconciliations of the differences between the non-GAAP financial measures and their most directly comparable GAAP financial measures. 2The company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably estimated. See "Use of Non-GAAP Measures" following the attached schedules for additional explanation. 3Other includes the following three operating segments: Nuclear and Precision Health Solutions (NPHS), at-Home Solutions and OptiFreight Logistics, which are not significant enough individually to require reportable segment disclosure. Cardinal Health uses its website as a channel of distribution for material company information. Important information, including news releases, financial information, earnings and analyst presentations, and information about upcoming presentations and events is routinely posted and accessible on the Investor Relations page at In addition, the website allows investors and other interested persons to sign up automatically to receive email alerts when the company posts news releases, SEC filings and certain other information on its website. Cautions concerning forward-looking statementsThis release contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook and various accruals and estimates. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These risks and uncertainties include the risk that we may fail to achieve our strategic objectives, including the continued execution of the GMPD Improvement Plan initiatives, whether as a result of tariffs on products we source or manufacture, an uncertain global economic and trade environment, Cardinal Health Brand sales or ongoing inflationary pressures; our ability to manage uncertainty with respect to certain government initiatives, including the Executive Order regarding "Most Favored Nation" pricing for branded prescription pharmaceuticals and the One Big Beautiful Bill Act; competitive pressures in Cardinal Health's various lines of business, including the risk that customers may reduce purchases made under their contracts with us or terminate or not renew their contracts, whether due to price increases or otherwise; risks associated with litigation matters, including a Department of Justice investigation focused on potential violations of the Anti-Kickback Statute and False Claims Act; the risk that events outside of our control, such as weather or geopolitical events, may impact demand for our products or may cause supply shortages that impact our cost and ability to fulfill customer demand; the performance of our generics program, including our ability to offset generic deflation and maintain other financial and strategic benefits through our generic sourcing venture or other components of our generics programs; risks associated with recently completed and pending acquisitions, including risks arising as a result from our entry into new lines of businesses. Cardinal Health is subject to additional risks and uncertainties described in Cardinal Health's Form 10-K, Form 10-Q and Form 8-K reports and exhibits to those reports. This release reflects management's views as of August 12, 2025. Except to the extent required by applicable law, Cardinal Health undertakes no obligation to update or revise any forward-looking statement. Forward-looking statements are aspirational and not guarantees or promises that goals, targets or projections will be met, and no assurance can be given that any commitment, expectation, initiative or plan in this report can or will be achieved or completed. Cardinal Health provides definitions and reconciliations of non-GAAP financial measures and their most directly comparable GAAP financial measures at Schedule 1 Cardinal Health, Inc. and Subsidiaries Consolidated Statements of Earnings (Unaudited) Fourth QuarterFiscal Year (in millions, except per common share amounts) 20252024% Change20252024% Change Revenue $ 60,159$ 59,867— %$ 222,578$ 226,827(2) % Cost of products sold 57,95757,985— %214,410219,413(2) % Gross margin 2,2021,88217 %8,1687,41410 % Operating expenses:Distribution, selling, general and administrative expenses 1,4841,27716 %5,3825,0008 % Restructuring and employee severance 276988175 Amortization and other acquisition-related costs 13377464284 Acquisition-related cash and share-based compensation costs 106—126— Impairments and (gain)/loss on disposal of assets, net 1 33818634 Litigation (recoveries)/charges, net (9)50(185)78 Operating earnings 4284017 %2,2751,24383 % Other (income)/expense, net (30)1(41)(9) Interest expense, net 749N.M.21551N.M. Earnings before income taxes 384391(2) %2,1011,20175 % Provision for income taxes 2 141158(11) %53234853 % Net earnings 2432334 %1,56985384 % Less: Net (earnings)/loss attributable to noncontrolling interests (4)2(8)(1) Net earnings attributable to Cardinal Health, Inc. $ 239$ 2352 %$ 1,561$ 85283 % Earnings per common share attributable to Cardinal Health, Inc.:Basic $ 1.01$ 0.965 %$ 6.48$ 3.4886 % Diluted 1.000.964 %6.453.4587 % Weighted-average number of common shares outstanding:Basic 239244241245 Diluted 2402452422471 Impairments and (gain)/loss on disposals of assets, net includes pre-tax goodwill impairment charges of $675 million related to the GMPD segment recorded in fiscal year ended June 30, 2024. 2 Provision for income taxes includes the tax effects relating to the cumulative goodwill impairment charges. For fiscal 2024, the net tax benefits related to the goodwill impairment charges was $58 million. Schedule 2 Cardinal Health, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (Unaudited) (in millions) June 30, 2025June 30, 2024 AssetsCurrent assets:Cash and equivalents $ 3,874$ 5,133 Trade receivables, net 13,24212,084 Inventories, net 16,83114,957 Prepaid expenses and other 2,4142,663 Assets held for sale 1247 Total current assets 36,37334,884 Property and equipment, net 2,8582,529 Goodwill and other intangibles, net 12,1776,450 Other assets 1,7141,258 Total assets $ 53,122$ 45,121 Liabilities and Shareholders' DeficitCurrent liabilities:Accounts payable $ 34,713$ 31,759 Current portion of long-term obligations and other short-term borrowings 550434 Other accrued liabilities 3,6343,447 Total current liabilities 38,89735,640 Long-term obligations, less current portion 7,9774,658 Deferred income taxes and other liabilities 8,8828,035 Total shareholders' deficit (2,634)(3,212) Total liabilities and shareholders' deficit $ 53,122$ 45,121 Schedule 3 Cardinal Health, Inc. and Subsidiaries Consolidated Statements of Cash Flows (Unaudited) Fourth QuarterFiscal Year (in millions) 2025202420252024 Cash flows from operating activities:Net earnings $ 243$ 233$ 1,569853 Adjustments to reconcile net earnings to net cash provided by operating activities:Depreciation and amortization 209186790710 Impairments and loss on sale of other investments 1232 Impairments and (gain)/loss on disposal of assets, net 33818634 Share-based compensation 15333244121 Provision for/(benefit from) deferred income taxes 243(104)243(104) Provision for bad debts 1285336 Change in operating assets and liabilities, net of effects from acquisitions and divestitures: Increase in trade receivables (466)(773)(833)(996) (Increase)/decrease in inventories (607)2,373(1,816)1,115 Increase/(decrease) in accounts payable 1,778(294)2,7321,824 Other accrued liabilities and operating items, net (72)410(606)(433) Net cash provided by operating activities 1,5272,0822,3973,762 Cash flows from investing activities:Acquisition of subsidiaries, net of cash acquired (1,395)2(5,250)(1,190) Additions to property and equipment (232)(193)(547)(511) Proceeds from net investment hedge terminations —6234 Purchase of short-term time deposits ———(550) Proceeds from short-term investment in time deposit —350200350 Other investing items, net (4)1218 Net cash provided by/(used in) investing activities (1,631)166(5,593)(1,849) Cash flows from financing activities:Proceeds from long-term obligations, net of issuance costs 800—3,6691,139 Purchases and payments of noncontrolling interests, net (12)—(12)— Reduction of long-term obligations (11)(760)(445)(783) Net tax proceeds from share-based compensation (1)23(13)46 Dividends on common shares (120)(122)(494)(499) Purchase of treasury shares ——(765)(750) Net cash provided by/(used in) financing activities 656(859)1,940(847) Effect of exchange rates changes on cash and equivalents (4)(2)(3)(9) Net increase/(decrease) in cash and equivalents 5481,387(1,259)1,057 Cash and equivalents at beginning of period 3,3263,7465,1334,076 Cash and equivalents at end of period $ 3,874$ 5,133$ 3,874$ 5,133 Schedule 4 Cardinal Health, Inc. and Subsidiaries Segment Information (Unaudited) Fourth QuarterPharmaceutical and Specialty SolutionsGlobal Medical Products and DistributionOther (in millions) 202520242025202420252024 RevenueAmount $ 55,372$ 55,608$ 3,199$ 3,109$ 1,609$ 1,172 Growth rate — %13 %3 %2 %37 %15 % Segment profit Amount $ 535$ 482$ 70$ 47$ 160$ 111 Growth rate 11 %8 %49 %N.M.44 %11 % Segment profit margin 0.97 %0.87 %2.19 %1.51 %9.94 %9.47 % Fiscal YearPharmaceutical and Specialty SolutionsGlobal Medical Products and DistributionOther (in millions) 202520242025202420252024 RevenueAmount $ 204,644$ 210,019$ 12,636$ 12,381$ 5,382$ 4,512 Growth rate (3) %11 %2 %1 %19 %12 % Segment profitAmount $ 2,258$ 2,015$ 135$ 92$ 516$ 423 Growth rate 12 %7 %47 %N.M.22 %7 % Segment profit margin 1.10 %0.96 %1.07 %0.74 %9.59 %9.38 %The sum of the components and certain computations may reflect rounding adjustments. Schedule 5 Cardinal Health, Inc. and Subsidiaries GAAP / Non-GAAP Reconciliation1 (Unaudited) Net (Earnings)/ LossGrossOperating Earnings Provision AttributableNet Diluted MarginSG&A2Earnings Before for to Non-Earnings3 EffectiveEPS 3 (in millions, except per common share amounts) Gross GrowthGrowth Operating Growth Income Income Controlling Net Growth Tax Diluted Growth Margin Rate SG&A 2 Rate Earnings Rate Taxes Taxes Interests Earnings3 Rate Rate EPS 3 Rate Fourth Quarter 2025 GAAP $ 2,202 17 % $ 1,484 16 % $ 428 7 % $ 384 $ 141 $ (4) $ 239 2 % 36.9 % $ 1.00 4 % Restructuring and employee severance ——2727 6 — 21 0.09Amortization and other acquisition-related costs ——133133 23 2 112 0.46Acquisition-related cash & share-based compensation costs ——106106 1 4 109 0.45Impairments and (gain)/loss on disposal of assets, net ——3333 9 — 24 0.10Litigation (recoveries)/charges, net ——(9)(9) (2) — (7) (0.03)Non-GAAP $ 2,203 17 % $ 1,484 16 % $ 719 19 % $ 676 $ 178 $ 3 $ 501 11 % 26.3 % $ 2.08 13 % Fourth Quarter 2024 GAAP $ 1,882 5 % $ 1,277 2 % $ 401 N.M. $ 391 $ 158 $ 2 $ 235 N.M. 40.4 % $ 0.96 N.M. Restructuring and employee severance ——6969 13 — 56 0.23Amortization and other acquisition-related costs ——7777 19 — 58 0.24Impairments and (gain)/loss on disposal of assets, net 4 ——88 (32) — 40 0.16Litigation (recoveries)/charges, net ——5050 (12) — 62 0.25Non-GAAP $ 1,882 5 % $ 1,277 2 % $ 605 14 % $ 595 $ 147 $ 2 $ 450 23 % 24.6 % $ 1.84 29 %1 For more information on these measures, refer to the Use of Non-GAAP Measures and Definitions schedules. 2 Distribution, selling, general and administrative expenses. 3 Attributable to Cardinal Health, Inc. 4 During fiscal 2024, we recorded cumulative pre-tax goodwill impairment charges of $675 million related to GMPD in impairments and (gain)/loss on disposal of assets, net. The estimated net tax benefit related to the impairments is $58 million and is included in the annual effective tax rate. During the three months ended June 30, 2024, the amount of tax expense recognized related to goodwill impairment charges was $34 million, which reflects the reversal of the incremental tax benefit recognized during the nine months ended March 31, 2024. The sum of the components and certain computations may reflect rounding adjustments. We generally apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred. Schedule 5 Cardinal Health, Inc. and Subsidiaries GAAP / Non-GAAP Reconciliation1 (Unaudited) Net EarningsGrossOperating Earnings Provision AttributableNet Diluted MarginSG&A2Earnings Before for to Non-Earnings3 EffectiveEPS 3Gross GrowthGrowth Operating Growth Income Income Controlling Net Growth Tax Diluted Growth (in millions, except per common share amounts) Margin Rate SG&A 2 Rate Earnings Rate Taxes Taxes Interests Earnings3 Rate Rate EPS 3 Rate Fiscal Year 2025 GAAP $ 8,168 10 % $ 5,382 8 % $ 2,275 83 % $ 2,101 $ 532 $ (8) $ 1,561 83 % 25.3 % $ 6.45 87 % Restructuring and employee severance ——8888 21 — 67 0.28Amortization and other acquisition-related costs ——464464 104 — 360 1.49Acquisition-related cash & share-based compensation costs ——126126 1 — 125 0.51Impairments and (gain)/loss on disposal of assets, net ——1818 5 — 13 0.05Litigation (recoveries)/charges, net ——(185)(185) (54) — (131) (0.54)Non-GAAP $ 8,168 10 % $ 5,382 8 % $ 2,786 15 % $ 2,612 $ 609 $ (8) $ 1,995 7 % 23.3 % $ 8.24 9 % Fiscal Year 2024 GAAP $ 7,414 8 % $ 5,000 4 % $ 1,243 65 % $ 1,201 $ 348 $ (1) $ 852 N.M. 28.9 % $ 3.45 N.M. Shareholder cooperation agreement costs (1)11 — — 1 —Restructuring and employee severance ——175175 41 — 134 0.54Amortization and other acquisition-related costs ——284284 74 — 210 0.85Impairments and (gain)/loss on disposal of assets, net 4 ——634634 47 — 587 2.38Litigation (recoveries)/charges, net ——7878 5 — 73 0.30Non-GAAP $ 7,414 8 % $ 5,000 4 % $ 2,414 16 % $ 2,372 $ 515 $ (1) $ 1,856 21 % 21.7 % $ 7.53 29 % Fiscal Year 2023 GAAP $ 6,874 6 % $ 4,800 6 % $ 752 N.M. $ 663 $ 332 $ (1) $ 330 N.M. 50.0 % $ 1.26 N.M. State opioid assessment related to prior fiscal years —6(6)(6) (2) — (4) (0.02)Shareholder cooperation agreement costs —(8)88 2 — 6 0.02Restructuring and employee severance ——9595 21 — 74 0.28Amortization and other acquisition-related costs ——285285 74 — 211 0.80Impairments and (gain)/loss on disposal of assets, net 4 ——1,2461,246 108 — 1,138 4.35Litigation (recoveries)/charges, net ——(304)(304) (83) — (221) (0.84)Non-GAAP $ 6,874 6 % $ 4,798 6 % $ 2,076 5 % $ 1,987 $ 452 $ (1) $ 1,534 8 % 22.8 % $ 5.85 15 %1 For more information on these measures, refer to the Use of Non-GAAP Measures and Definitions schedules. 2 Distribution, selling, general and administrative expenses. 3 Attributable to Cardinal Health, Inc. 4 For fiscal 2024 and 2023, impairments and (gain)/loss on disposals of assets, net includes pre-tax goodwill impairment charges of $675 million and $1.2 billion related to the GMPD segment, respectively. For fiscal 2024 and 2023 the net tax benefit related to these charges was $58 million and $92 million, respectively, and were included in the annual effective tax rates. The sum of the components and certain computations may reflect rounding adjustments. We generally apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred. Schedule 6 Cardinal Health, Inc. and Subsidiaries GAAP / Non-GAAP Reconciliation - GAAP Cash Flow to Non-GAAP Adjusted Free Cash Flow (Unaudited) Fiscal Year (in millions) 20252024 GAAP - Cash Flow CategoriesNet cash provided by operating activities $ 2,397$ 3,762 Net cash used in investing activities (5,593)(1,849) Net cash provided by/(used in) financing activities 1,940(847) Effect of exchange rates changes on cash and equivalents (3)(9) Net increase/(decrease) in cash and equivalents $ (1,259)$ 1,057 Non-GAAP Adjusted Free Cash FlowNet cash provided by operating activities $ 2,397$ 3,762 Additions to property and equipment (547)(511) Payments related to matters included in litigation (recoveries)/charges, net 619691 Non-GAAP Adjusted Free Cash Flow $ 2,469$ 3,942 For more information on these measures, refer to the Use of Non-GAAP Measures and Definitions schedules. Schedule 7 Cardinal Health, Inc. and Subsidiaries Revenue Growth Rates Excluding OptumRx (Unaudited) Fourth Quarter Consolidated Pharmaceutical and Specialty Solutions (in millions) 20252024Growth Rate(in millions) 20252024Growth Rate Total Revenue $ 60,159$ 59,867— %Total Pharmaceutical and SpecialtySolutions Revenue $ 55,372$ 55,608— % less: OptumRx Revenue —10,287less: OptumRx Revenue —10,287 Revenue, excluding OptumRx $ 60,159$ 49,58021 %Pharmaceutical and Specialty SolutionsRevenue, excluding OptumRx $ 55,372$ 45,32122 %Year-to-Date Consolidated Pharmaceutical and Specialty Solutions (in millions) 20252024Growth Rate(in millions) 20252024Growth Rate Total Revenue $ 222,578$ 226,827(2) %Total Pharmaceutical and SpecialtySolutions Revenue $ 204,644$ 210,019(3) % less: OptumRx Revenue —38,112less: OptumRx Revenue —38,112 Revenue, excluding OptumRx $ 222,578$ 188,71518 %Pharmaceutical and Specialty SolutionsRevenue, excluding OptumRx $ 204,644$ 171,90719 % Cardinal Health, Inc. and Subsidiaries Use of Non-GAAP MeasuresThis earnings release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles ("GAAP"). In addition to analyzing our business based on financial information prepared in accordance with GAAP, we use these non-GAAP financial measures internally to evaluate our performance, engage in financial and operational planning, and determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business. We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors. However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth below should be carefully evaluated. Exclusions from Non-GAAP Financial MeasuresManagement believes it is useful to exclude the following items from the non-GAAP measures presented in this report for its own and for investors' assessment of the business for the reasons identified below: LIFO charges and credits are excluded because the factors that drive last-in first-out ("LIFO") inventory charges or credits, such as pharmaceutical manufacturer price appreciation or deflation and year-end inventory levels (which can be meaningfully influenced by customer buying behavior immediately preceding our fiscal year-end), are largely out of our control and cannot be accurately predicted. The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies' financial results. We did not recognize any LIFO charges or credits during the periods presented. State opioid assessments related to prior fiscal years is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the period in which the expense is incurred. This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business. Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items. Income from state opioid assessments related to prior fiscal years represents reversals of accruals due to changes in estimates or when the underlying assessments were invalidated by a Court or reimbursed by manufacturers. Shareholder cooperation agreement costs includes costs such as legal, consulting, and other expenses incurred in relation to the agreement (the "Cooperation Agreement") entered into among Elliott Associates, L.P., Elliott International, L.P. (together, "Elliott"), and Cardinal Health. These include costs incurred to negotiate and finalize the Cooperation Agreement and costs incurred by the Business Review Committee of the Board of Directors, formed under this Cooperation Agreement, tasked with undertaking a comprehensive review of our strategy, portfolio, capital allocation framework, and operations. We have excluded these costs from our non-GAAP metrics because they do not occur in or reflect the ordinary course of our ongoing business operations and may obscure analysis of trends and financial performance. The Cooperation Agreement expired in the second quarter of fiscal 2025. Restructuring and employee severance costs are excluded because they are not part of the ongoing operations of our underlying business and include, but are not limited to, costs related to divestitures, closing and consolidating facilities, changing the way we manufacture or distribute our products, moving manufacturing of a product to another location, changes in production or business process outsourcing or insourcing, employee severance, and realigning operations. Amortization and other acquisition-related costs, which include transaction costs, integration costs, and changes in the fair value of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results. Additionally, costs for amortization of acquisition-related intangible assets and amortization as a result of basis differences in equity method investments are non-cash amounts, which are variable in amount and frequency and are significantly impacted by the timing and size of acquisitions, so their exclusion facilitates comparison of historical, current, and forecasted financial results. We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity's initial balance sheet as part of the purchase price allocation. These costs are also significantly impacted by the timing, complexity, and size of acquisitions. Acquisition-related cash and share-based compensation costs are incurred in connection with contingent cash payments or the issuance of share-based payment awards, which include service requirements, as a part of certain physician practice acquisitions. These costs include fair value adjustments for liability-classified awards. These costs are excluded because they are unrelated to the underlying operating results of our business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results. In addition, the magnitude of these expenses is significantly impacted by the timing and size of the acquisitions of physician practices. Impairments and gain or loss on disposal of assets, net are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current, and forecasted financial results. Litigation recoveries or charges, net are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business, and are inherently unpredictable in timing and amount. Loss on early extinguishment of debt is excluded because it does not typically occur in the normal course of business and may obscure analysis of trends and financial performance. Additionally, the amount and frequency of this type of charge is not consistent and is significantly impacted by the timing and size of debt extinguishment transactions. The tax effect for each of the items listed above is determined using the tax rate and other tax attributes applicable to the item and the jurisdiction(s) in which the item is recorded. The gross, tax, and net impact of each item are presented with our GAAP to non-GAAP reconciliations. Non-GAAP adjusted free cash flow: We provide this non-GAAP financial measure as a supplemental metric to assist readers in assessing the effects of items and events on our cash flow on a year-over-year basis and in comparing our performance to that of our peer group companies. In calculating this non-GAAP metric, certain items are excluded from net cash provided by operating activities because they relate to significant and unusual or non-recurring events and are inherently unpredictable in timing and amount. We believe adjusted free cash flow is important to management and useful to investors as a supplemental measure as it indicates the cash flow available for working capital needs, debt repayments, dividend payments, share repurchases, strategic acquisitions, or other strategic uses of cash. A reconciliation of our GAAP financial results to Non-GAAP adjusted free cash flow is provided in Schedule 6 of the financial statement tables included with this release. Forward Looking Non-GAAP MeasuresIn this document, the Company presents certain forward-looking non-GAAP metrics. The Company does not provide outlook on a GAAP basis because the items that the Company excludes from GAAP to calculate the comparable non-GAAP measure can be dependent on future events that are less capable of being controlled or reliably predicted by management and are not part of the Company's routine operating activities. Additionally, management does not forecast many of the excluded items for internal use and therefore cannot create or rely on outlook done on a GAAP basis. The occurrence, timing and amount of any of the items excluded from GAAP to calculate non-GAAP could significantly impact the Company's fiscal 2025 GAAP results. Over the past five fiscal years, the excluded items have impacted the Company's EPS from $1.79 to $8.44, which includes a $6.97 change related to the goodwill impairment we recognized in fiscal 2022. DefinitionsGrowth rate calculation: growth rates in this report are determined by dividing the difference between current period results and prior period results by prior period results. Interest and Other, net: other (income)/expense, net plus interest expense, net. Segment Profit: segment revenue minus (segment cost of products sold and segment distribution, selling, general and administrative expenses). Segment Profit margin: segment profit divided by segment revenue. Non-GAAP gross margin: gross margin, excluding LIFO charges/(credits). Non-GAAP distribution, selling, general and administrative expenses or Non-GAAP SG&A: distribution, selling, general and administrative expenses, excluding state opioid assessment related to prior fiscal years and shareholder cooperation agreement costs. Non-GAAP operating earnings: operating earnings excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) shareholder cooperation agreement costs, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) acquisition-related cash and share-based compensation costs, (7) impairments and (gain)/loss on disposal of assets, net, and (8) litigation (recoveries)/charges, net. Non-GAAP earnings before income taxes: earnings before income taxes excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) shareholder cooperation agreement costs, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) acquisition-related cash and share-based compensation costs, (7) impairments and (gain)/loss on disposal of assets, net, (8) litigation (recoveries)/charges, net, and (9) loss on early extinguishment of debt. Non-GAAP net earnings attributable to non-controlling interests: net earnings attributable to non-controlling interests excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) shareholder cooperation agreement costs, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) acquisition-related cash and share-based compensation costs, (7) impairments and (gain)/loss on disposal of assets, net, (8) litigation (recoveries)/charges, net, and (9) loss on early extinguishment of debt, each net of tax. Non-GAAP net earnings attributable to Cardinal Health, Inc.: net earnings attributable to Cardinal Health, Inc. excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) shareholder cooperation agreement costs, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) acquisition-related cash and share-based compensation costs, (7) impairments and (gain)/loss on disposal of assets, net, (8) litigation (recoveries)/charges, net, and (9) loss on early extinguishment of debt, each net of tax. Non-GAAP effective tax rate: provision for income taxes adjusted for the tax impacts of (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) shareholder cooperation agreement costs, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) acquisition-related cash and share-based compensation costs, (7) impairments and (gain)/loss on disposal of assets, net, (8) litigation (recoveries)/charges, net, and (9) loss on early extinguishment of debt divided by (earnings before income taxes adjusted for the items above). Non-GAAP diluted earnings per share attributable to Cardinal Health, Inc.: non-GAAP net earnings attributable to Cardinal Health, Inc. divided by diluted weighted-average shares outstanding. Non-GAAP adjusted free cash flow: net cash provided by operating activities less payments related to additions to property and equipment, excluding settlement payments and receipts related to matters included in litigation (recoveries)/charges, net, as defined above, or other significant and unusual or non-recurring cash payments or receipts. View original content to download multimedia: SOURCE Cardinal Health, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
08-08-2025
- Business
- Yahoo
Do Wall Street Analysts Like Cardinal Health Stock?
With a market cap of $37.4 billion, Cardinal Health, Inc. (CAH) is a leading Ohio-based healthcare services and products company specializing in pharmaceutical distribution and medical supply manufacturing. It serves over 100,000 locations globally, serving hospitals, pharmacies, and healthcare providers. CAH shares have delivered an impressive rally, soaring 53.9% over the past 52 weeks and are up 29.7% in 2025, outpacing the S&P 500 Index's ($SPX) 21.9% gains over the past year and a 7.8% surge on a YTD basis. More News from Barchart Cathie Wood Is Buying Shares of This Little-Known Ethereum Treasury Company. Should You? Dear Ford Stock Fans, Mark Your Calendar for August 11 Robinhood Stock Seemingly Can't Be Stopped in 2025. Is It Too Late to Buy HOOD Here? Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! Zooming in further, CAH has also surpassed the SPDR S&P Health Care Services ETF's (XHS) 5.2% fall over the past year and 1.5% dip in 2025. On Jul. 30, Cardinal's shares rose marginally after the company announced the expansion of its Equity Rx program, aimed at supporting individuals in Ohio and beyond who cannot afford prescription medications. Initially launched as a pilot in Ohio in 2023 through a partnership with the Cardinal Health Foundation, the Charitable Healthcare Network, and St. Vincent de Paul Charitable Pharmacy, the initiative has now received a total investment of $5 million from the Foundation. For the year that ended in June 2025, analysts expect Cardinal's earnings to grow 8.6% year-over-year to $8.18 per share. Furthermore, the company has a solid earnings surprise history. It surpassed the Street's bottom-line expectations in each of the past four quarters. Among the 14 analysts covering the CAH stock, the consensus rating is a 'Strong Buy.' That's based on 11 'Strong Buy' and three 'Hold' ratings. This configuration is more bullish than three months ago, when the stock had 10 'Strong Buy' ratings. On July 16, Morgan Stanley (MS) raised its price target for Cardinal Health from $181 to $190 while reiterating its 'Overweight' rating, signaling continued confidence in the company's growth prospects. CAH's mean price target of $180.33 suggests a 16.3% premium to current price levels, while its Street-high target of $197 indicates a 28.4% upside potential. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Hindu
31-07-2025
- Politics
- The Hindu
CSI Synod condemns arrest of two nuns in Chhattisgarh
Church of South India (CSI) Synod Secretariat has condemned the arrest of two nuns in Chhattisgarh and demanded their immediate release and an end to religious intimidation. In a statement issued here on Thursday (July 31, 2025), CSI Synod general secretary C. Fernandas Rathina Raja said the CSI expresses its deep anguish and strong condemnation over the recent arrest of two Catholic nuns. 'This action, reportedly based on unfounded accusations, is not only unjust but also reveals a disturbing trend of targeting Christian religious personnel under the guise of law and order'. Church of South India Synod is the highest administrative body of the CSI that administers 24 Dioceses in South India and Jaffna in Sri Lanka. The statement said was it was deeply troubling that the women, who have committed their lives to serving the poor, the sick and the marginalised are being subjected to harassment and humiliation without credible evidence. 'Such acts not only violate the fundamental rights but also infringe upon the constitutional guarantee of religious freedom and the right to practice and propagate one's faith,' the statement noted. The CSI Synod called upon the Government of Chhattisgarh and the concerned law enforcement authorities to immediately withdraw the false cases, release the nuns unconditionally and ensure their dignity and safety. It is the duty of the State to protect all citizens equally, irrespective of their faith, and to ensure that communal elements do not misuse administrative mechanisms to intimidate religious minorities, it said. 'The CSI stand in solidarity with our sisters and the Christian community in Chhattisgarh,' Mr. Rathina Raja said adding that the organisation reaffirms its steadfast commitment to truth, justice and harmony and would continue to raise it voice against all forms of religious intolerance and persecution. This act indicting the innocent religious, just to satisfy the political apatite of the communal activists supported by the government is unjust and highly condemnable. Hence we request all the faithful across all denominations to gather in large numbers to extend our solidarity demanding justice, immediate release of the nuns and punishment to the perpetrators. Peace rally The Catholic Association of Hyderabad (CAH) has given a call to hold peace rally this evening on July 31 in the City. The peace rally would start from St. Francis High School in Secunderabad and conclude near the Mother Theresa Statue in Regimental bazar, according to CAH release. The CAH said the act of indicting the innocent religious, just to satisfy the political apetite of the communal activists supported by the government is unjust and highly condemnable.
